ALPS Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-84,092
| Closed | -$1.8M | – | 1182 |
|
|
2026
Q1 | $1.8M | Sell |
84,092
-212
| -0.3% | -$2.99K | 0.01% | 429 |
|
|
2025
Q4 | $786K | Buy |
84,304
+35,269
| +72% | +$295K | ﹤0.01% | 627 |
|
|
2025
Q3 | $346K | Sell |
49,035
-5,673
| -10% | -$39K | ﹤0.01% | 936 |
|
|
2025
Q2 | $356K | Sell |
54,708
-18,635
| -25% | -$128K | ﹤0.01% | 857 |
|
|
2025
Q1 | $582K | Sell |
73,343
-8,206
| -10% | -$88.4K | ﹤0.01% | 572 |
|
|
2024
Q4 | $1.03M | Buy |
81,549
+12,240
| +18% | +$170K | 0.01% | 473 |
|
|
2024
Q3 | $965K | Buy |
69,309
+1,139
| +2% | +$16.3K | 0.01% | 496 |
|
|
2024
Q2 | $939K | Buy |
68,170
+6,539
| +11% | +$95.7K | 0.01% | 479 |
|
|
2024
Q1 | $1.02M | Buy |
61,631
+1,936
| +3% | +$29K | 0.01% | 482 |
|
|
2023
Q4 | $872K | Sell |
59,695
-4,458
| -7% | -$54K | 0.01% | 513 |
|
|
2023
Q3 | $787K | Buy |
64,153
+1,592
| +3% | +$20.8K | 0.01% | 523 |
|
|
2023
Q2 | $747K | Buy |
62,561
+14,078
| +29% | +$184K | 0.01% | 545 |
|
|
2023
Q1 | $648K | Sell |
48,483
-1,373
| -3% | -$26.8K | 0.01% | 543 |
|
|
2022
Q4 | $1.07M | Buy |
49,856
+9,712
| +24% | +$199K | 0.01% | 461 |
|
|
2022
Q3 | $804K | Buy |
40,144
+3,414
| +9% | +$72.6K | 0.01% | 509 |
|
|
2022
Q2 | $657K | Sell |
36,730
-26,941
| -42% | -$278K | 0.01% | 536 |
|
|
2022
Q1 | $632K | Sell |
63,671
-7,997
| -11% | -$106K | 0.01% | 398 |
|
|
2021
Q4 | $1.21M | Buy |
+71,668
| New | +$1.47M | 0.01% | 336 |
|
Other funds holding DAWN
ALPS Advisors's DAWN Position: Q2 2026 in Review
ALPS Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 84,092 shares — an estimated $1.8M sold.
ALPS Advisors first reported a position in DAWN in Q4 2021 and held it in 18 quarters. The position peaked at $1.8M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- ALPS Advisors reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- ALPS Advisors sold 84,092 Day One Biopharmaceuticals shares in Q2 2026, an estimated $1.8M.
- ALPS Advisors first reported a position in Day One Biopharmaceuticals in Q4 2021 and held it in 18 quarters.
- ALPS Advisors's Day One Biopharmaceuticals position peaked at $1.8M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.